Show simple item record

dc.contributor.authorDixon, Dave L. et al.
dc.description.abstractA novel betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly across the globe since December 2019. Coronavirus disease 2019 (COVID-19) has a significantly higher mortality rate than seasonal influenza and has disproportionately affected older adults, especially those with cardiovascular disease and related risk factors. Adverse cardiovascular sequalae, such has myocarditis, acute myocardial infarction, and heart failure, have been reported in patients with COVID-19. No established treatment is currently available; however, several therapies, including remdesivir, hydroxychloroquine and chloroquine, and interleukin (IL)-6 inhibitors, are being used off-label and evaluated in ongoing clinical trials. Considering these therapies are not familiar to cardiovascular clinicians managing these patients, this review describes the pharmacology of these therapies in the context of their use in patients with cardiovascular-related conditions.en_US
dc.subjectCardiovascular Diseasesen_US
dc.subjectInfectious Diseasesen_US
dc.subjectMyocardial Infarctionen_US
dc.titleCardiovascular Considerations in Treating Patients with Coronavirus (COVID-19)en_US
eihealth.categoryClinical characterization and managementen_US
eihealth.typeOther publicationsen_US
eihealth.maincategorySave Lives / Salvar Vidasen_US
dc.relation.ispartofjournalJournal of Cardiovascular Pharmacologyen_US

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record